Literature DB >> 26657278

Sustainability of the Peritoneal Dialysis-First Policy in Hong Kong.

Agnes Shin-Man Choy1, Philip Kam-Tao Li.   

Abstract

In Hong Kong, the average annual cost of haemodialysis (HD) per patient is more than double of that of peritoneal dialysis (PD). As the number of patients with end-stage renal disease (ESRD) has surged, it has posed a great financial burden to the government and society. A PD-first policy has been implemented in Hong Kong for three decades based on its cost-effectiveness, and has achieved successful outcomes throughout the years. A successful PD-first policy requires medical expertise in PD, the support of dedicated staff and a well-designed patient training programme. Addressing patients' PD problems is the key to sustainability of the PD-first policy. In this article, we highlight three important groups of patients: those with frequent peritonitis, ultrafiltration failure or inadequate dialysis. Potential strategies to improve the outcomes of these groups will be discussed. Moreover, enhancing HD as back-up support and promoting organ transplantation are needed in order to maintain sustainability of the PD-first policy.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26657278     DOI: 10.1159/000441580

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

Review 1.  Transition Between Different Renal Replacement Modalities: Gaps in Knowledge and Care-The Integrated Research Initiative.

Authors:  Christopher Chan; Gill Combes; Simon Davies; Fred Finkelstein; Catherine Firanek; Rafael Gomez; Kitty J Jager; Vivek Jha George; David W Johnson; Mark Lambie; Magdalena Madero; Ikuto Masakane; Stephen McDonald; Madhukar Misra; Sandip Mitra; Thyago Moraes; Annie-Claire Nadeau-Fredette; Purna Mukhopadhyay; Jeff Perl; Ronald Pisoni; Bruce Robinson; Dong-Ryeol Ryu; Rajiv Saran; James Sloand; Nidhi Sukul; Allison Tong; Cheuk-Chun Szeto; Wim Van Biesen
Journal:  Perit Dial Int       Date:  2019 Jan-Feb       Impact factor: 1.756

Review 2.  Dialysis Provision and Implications of Health Economics on Peritoneal Dialysis Utilization: A Review from a Malaysian Perspective.

Authors:  Mohd Rizal Abdul Manaf; Naren Kumar Surendra; Abdul Halim Abdul Gafor; Lai Seong Hooi; Sunita Bavanandan
Journal:  Int J Nephrol       Date:  2017-10-31

3.  Economic Burden and Medical Insurance Impact of the Different Dialysis for End-stage Renal Diseases.

Authors:  Dan Gao; Sanhui Jing; Jian Wu; Ge Wu
Journal:  Iran J Public Health       Date:  2018-11       Impact factor: 1.429

4.  Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.

Authors:  Carlos K H Wong; Julie Chen; Samuel K S Fung; Maggie Mok; Yuk Lun Cheng; Irene Kong; Wai Kei Lo; Sing Leung Lui; T M Chan; Cindy L K Lam
Journal:  BMC Nephrol       Date:  2020-02-04       Impact factor: 2.388

5.  Barriers to Peritoneal Dialysis in Saskatchewan Canada: Results From a Province-Wide Survey.

Authors:  Bhanu Prasad; Maryam Jafari; Sachin Shah; Connie McNaught; Lucas Diebel
Journal:  Can J Kidney Health Dis       Date:  2020-12-16

6.  The role of personal attitudes of control and responsibility for the uptake of peritoneal dialysis- a national survey among dialysis patients.

Authors:  Isabell Schellartz; Tim Ohnhaeuser; Thomas Mettang; Nadine Scholten
Journal:  BMC Nephrol       Date:  2021-03-24       Impact factor: 2.388

Review 7.  Peritoneal dialysis: the ideal bridge from conservative therapy to kidney transplant.

Authors:  Sydney C W Tang; Kar Neng Lai
Journal:  J Nephrol       Date:  2020-07-11       Impact factor: 3.902

8.  Tackling Dialysis Burden around the World: A Global Challenge.

Authors:  Philip Kam-Tao Li; Gordon Chun-Kau Chan; Jianghua Chen; Hung-Chun Chen; Yuk-Lun Cheng; Stanley L-S Fan; John Cijiang He; Weixin Hu; Wai-Hon Lim; York Pei; Boon Wee Teo; Ping Zhang; Xueqing Yu; Zhi-Hong Liu
Journal:  Kidney Dis (Basel)       Date:  2021-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.